Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $ ...

Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a ...

United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The company has a market cap of $13.80 billion, a PE ratio of 13.49, a price-to-earnings-growth ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported fourth-quarter net income of $301.3 million. The Silver Spring, Maryland-based ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...